(CALA) - Earnings & Price History

CALA: - 16, $581.81M, -0.10 (-0.62%)

Sector: Healthcare - Industry: Biotechnology

Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate includes CB-839, an inhibitor of glutaminase, which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. The company has a license agreement with Mars, Inc. to develop and commercialize Symbiosciences portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.Key Statistics

Past CALA reports
Earning DateTimeTitleEPS-e EPS-a ClosePrev CloseOpen Day LowDay High Gap % CFO %Change % Volume
2017-03-16-0.4812.413.713.411.713.75-2.19%-7.46%-9.49%1.14M
2016-11-09-0.542.952.7532.8539.09%▲-1.67%7.27%133.82K
2016-08-09-0.523.053.263.1533.29-3.37%-3.17%-6.44%259.30K
2016-05-10-0.474.474.664.534.424.74-2.79%-1.32%-4.08%112.86K
2016-03-15-0.565.556.496.755.464.01%-17.78%-14.48%54.02K
2015-11-09-0.526.7157.837.126.597.595-9.07%▲-5.69%-14.24%745.21K
2015-08-10-0.455.756.646.415.736.62-3.46%-10.30%-13.40%1.31M
2015-05-07-0.4713.879.5210.510.1414.0610.29%32.10%45.69%4.54M
2015-03-26AMC-0.4717.4515.8815.871518.44-0.06%9.96%9.89%518.10K

Login | Register
Monday Nov 20, 2017   EST
Enter a Ticker:

Economic Calendar

AAII Sentiment Survey

BULL^ neut ^ BEAR

Chart

index chart
index color
SPY257.6450.500.19%41,867,194

Upgrades/Downgrades